Viral capsid polypeptides

Patent metadata

Field	Value
Publication number	US-2023002451-A1
Application number	US-202017774306-A
Country	US
Kind code	A1
Filing date	Nov 6, 2020
Priority date	Nov 8, 2019
Publication date	Jan 5, 2023
Grant date	—

Abstract

The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polypeptides described herein.

First claim

What is claimed is:

1 . A viral capsid polypeptide bearing a mutation relative to SEQ ID NO: 2 (WT AAV2) in a region corresponding to amino acids 561-588.

2 . The viral capsid polypeptide of claim 1 , wherein the region corresponding to amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.

3 . The viral capsid polypeptide of claim 1 , which is an AAV capsid polypeptide.

4 . The viral capsid polypeptide of claim 1 , which is an AAV2 capsid polypeptide.

5 . An AAV VP1 capsid polypeptide bearing a mutation in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.

6 . The AAV VP1 capsid polypeptide of claim 5 , wherein the region corresponding to amino acids 561-588 of SEQ ID NO: 2 comprises a sequence selected from SEQ ID NO: 4-41,337.

7 . The AAV VP1 capsid polypeptide of claim 5 , which is an AAV2 capsid polypeptide.

8 . A viral capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.

9 . A variant of the viral capsid polypeptide of SEQ ID NO: 2, wherein the region of amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.

10 . An AAV2 capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.

11 . A nucleic acid encoding the capsid polypeptide of any one of claims 1 - 10 .

12 . An engineered AAV vector having at least capsid polypeptide comprising any one of the capsid polypeptides of claims 1 - 10 .

13 . A viral particle comprising a capsid polypeptide of any one of claims 1 - 10 .

14 . A method for delivering a payload, the method comprising contacting a cell with any of the engineered AAV vectors of claim 12 , or viral particles of claim 13 .

15 . The method of claim 14 , wherein the contacting is sufficient to allow for expression of the payload in the cell.

16 . A method for administering a payload, the method comprising administering to a subject any of the engineered AAV vectors of claim 12 , or viral particles of claim 13 .

17 . The method of claim 16 , wherein the administering is sufficient to allow for expression of the payload in the cell.

18 . The method of any of claims 14 - 17 , wherein the payload is selected from the group consisting of: a nucleic acid, a polypeptide, an inhibitory RNA, an antibody or antibody reagent, an oligonucleotide, and a miRNA.

Assignees

• Harvard College

Inventors

• Kelsic Eric
• Sinai Sam
• Ogden Pierce
• Church George M

Classifications

• C12N2750/14122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/861

  Adenoviral vectors · CPC title

• C07K14/075 Primary

  Adenoviridae · CPC title